Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Millennium, Compugen In Deal For Protein Pathway Software

March 27, 2002

By Rachelle H.B. Fishman

Ester Neurosciences Gets OK For Myasthenia Gravis Trials

Feb. 27, 2002

By Rachelle H.B. Fishman

Teva’s Copaxone Failure In MS Attributed To Low Relapse Rate

Feb. 22, 2002

By Rachelle H.B. Fishman

Budget Cuts Sidetrack Plan For Israeli Biotech Institute

Jan. 9, 2002

By Rachelle H.B. Fishman

Novartis Enlists Optimata To Analyze New Drug Candidates

Jan. 9, 2002

By Rachelle H.B. Fishman

MS Drugs Spur 33 Percent Growth In Israeli Biotech

May 30, 2001

By Rachelle H.B. Fishman

Mindsense Biosystems Secures $2M For Biomarkers Technology

May 23, 2001

By Rachelle H.B. Fishman

Compugen Contributes Data To Gene Ontology Consortium

May 16, 2001

By Rachelle H.B. Fishman

Israeli Biotech Industry Keeps Going Despite Political Turmoil

May 16, 2001

By Rachelle H.B. Fishman

Clal Biotechnology Establishes Center To Help Israeli Start-Ups

March 21, 2001

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...